Article(id=1329906153464640206, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329906092722728984, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2025.12.003, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1746115200000, receivedDateStr=2025-05-02, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1795003935447, onlineDateStr=2026-11-18, pubDate=1765296000000, pubDateStr=2025-12-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1795003935447, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1795003935447, creator=13701087609, updateTime=1795003935447, updator=13701087609, issue=Issue{id=1329906092722728984, tenantId=1146029695717560320, journalId=1319690259887390882, year='2025', volume='56', issue='12', pageStart='1493', pageEnd='1610', issueExtLink='null', onlineDate='null', pubDate='1765296000000', pubDateStr='2025-12-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=0, createTime=1795003920965, creator='13701087609', updateTime=1795004306301, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329907709501092294, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329906092722728984, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329907709501092295, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1329906092722728984, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1514, endPage=1523, ext={EN=ArticleExt(id=1329906153657578191, articleId=1329906153464640206, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=Current Status of Enteral Tube Administration Guidelines and Overview of in vitro Comparative Testing Evaluation, columnId=1325194059773522066, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Perspectives & Review, runingTitle=null, highlight=null, articleAbstract=

Enteral tube administration is an important oral alternative treatment route for patients with dysphagia.However, its clinical application faces multiple challenges, such as insufficient standardization, lack of guidance in drug package inserts, and an immature in vitro evaluation system. The U.S. FDA has issued enteral tube administration technical guidelines for more than 30 types of drugs(e.g., esomeprazole capsules, rivaroxaban tablets), clearly specifying test parameters(including enteral tube diameter, types and volumes of dispersion medium, incubation time). Currently, the problem of missing or incomplete information related to enteral tube administration in the package inserts of generic drugs in China is prominent, which may lead to clinical operation errors and risks to drug stability. This article reviews the relevant technical guidelines for enteral tube administration, the current status and research progress of clinical applications at home and abroad, as well as the existing problems. It focuses on summarizing the key points to be noted when conducting in vitro comparative studies, aiming to provide technical suggestions for the design, implementation, and result evaluation of in vitro tests for oral drugs administered via enteral tubes.

, authors=Jie ZHUANG1, 2, Mengjie QI1, Wenjing ZHANG1, Jianzhao NIU1, Qian LIU1, *, authorsList=Jie ZHUANG, Mengjie QI, Wenjing ZHANG, Jianzhao NIU, Qian LIU, authorCompany=null, correspAuthors=Qian LIU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329906153955373777, articleId=1329906153464640206, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=肠内管给药指导原则现状及体外对比试验评价概述, columnId=1322624444544176331, journalTitle=中国医药工业杂志, columnName=专论与综述, runingTitle=null, highlight=null, articleAbstract=

肠内管给药是吞咽障碍患者重要的口服替代治疗途径,但其临床应用面临标准化不足、药物说明书指导缺失及体外评价体系待完善等多重挑战。美国FDA已发布了30余种药品(如艾司奥美拉唑胶囊、利伐沙班片等)肠内管给药技术指南,明确了试验参数(肠内管管径、分散介质种类与体积、孵育时间等)。目前,我国仿制药说明书中的肠内管给药信息缺失或不完整问题突出,可能导致临床操作误差及药物稳定性风险。该文围绕经肠内管给药的相关技术指南、国内外临床应用现状和研究进展,以及目前存在的问题进行综述,重点总结开展体外对比研究时需要注意的关键点,以期为经肠内管给药的口服药物体外试验的设计、实施以及结果评价提供技术建议。

, authors=庄杰1, 2, 綦梦洁1, 张文婧1, 牛剑钊1, 刘倩1, *, authorsList=庄杰, 綦梦洁, 张文婧, 牛剑钊, 刘倩, authorCompany=null, correspAuthors=刘倩, authorNote=

庄杰,硕士研究生,专业方向:药物质量控制。

, correspAuthorsNote=
刘倩,博士,研究员,从事药物质量控制的研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=C9GYxZMzRHbHYTb6hJXLjA==, magXml=x4Ehh+nkG3aFTP31DZyvhg==, pdfUrl=null, pdf=CUaJJkQMd59Vx9oPbqr9zg==, pdfFileSize=1091720, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=QvaJSVeJtTOiXPLZjH3s2w==, mapNumber=null, fund=null)}, authors=[Author(id=1329906154362221274, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329906154441913053, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154362221274, language=EN, stringName=Jie ZHUANG, firstName=Jie, middleName=null, lastName=ZHUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.China National Institutes for Food and Drug Control, Beijing 100050
2.China Pharmaceutical University, Nanjing 210009, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329906154538382046, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154362221274, language=CN, stringName=庄杰, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中国食品药品检定研究院,北京 100050
2.中国药科大学,江苏 南京 210009, bio={"content":"

庄杰,硕士研究生,专业方向:药物质量控制。

"}, bioImg=null, bioContent=

庄杰,硕士研究生,专业方向:药物质量控制。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)]), AuthorCompany(id=1329906154282529493, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=2., ext=[AuthorCompanyExt(id=1329906154290918102, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154282529493, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China Pharmaceutical University, Nanjing 210009), AuthorCompanyExt(id=1329906154299306711, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154282529493, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国药科大学,江苏 南京 210009)])]), Author(id=1329906154626462432, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329906154689376994, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154626462432, language=EN, stringName=Mengjie QI, firstName=Mengjie, middleName=null, lastName=QI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.China National Institutes for Food and Drug Control, Beijing 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329906154756485859, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154626462432, language=CN, stringName=綦梦洁, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国食品药品检定研究院,北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)])]), Author(id=1329906154819400421, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329906154903286503, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154819400421, language=EN, stringName=Wenjing ZHANG, firstName=Wenjing, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.China National Institutes for Food and Drug Control, Beijing 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329906154962006760, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154819400421, language=CN, stringName=张文婧, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国食品药品检定研究院,北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)])]), Author(id=1329906155037504234, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329906155146556140, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906155037504234, language=EN, stringName=Jianzhao NIU, firstName=Jianzhao, middleName=null, lastName=NIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.China National Institutes for Food and Drug Control, Beijing 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329906155238830829, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906155037504234, language=CN, stringName=牛剑钊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国食品药品检定研究院,北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)])]), Author(id=1329906155360465647, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329906155498877681, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906155360465647, language=EN, stringName=Qian LIU, firstName=Qian, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.China National Institutes for Food and Drug Control, Beijing 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329906155570180850, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906155360465647, language=CN, stringName=刘倩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国食品药品检定研究院,北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)])])], keywords=[Keyword(id=1329906155683427059, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=EN, orderNo=1, keyword=enteral tube administration), Keyword(id=1329906155737953012, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=EN, orderNo=2, keyword=lack of information in the drug package insert), Keyword(id=1329906155830227701, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=EN, orderNo=3, keyword=in vitro test), Keyword(id=1329906155897336566, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=EN, orderNo=4, keyword=comparative study), Keyword(id=1329906155956056823, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=EN, orderNo=5, keyword=drug stability), Keyword(id=1329906156023165688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=EN, orderNo=6, keyword=standardized procedure), Keyword(id=1329906156081885945, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=CN, orderNo=1, keyword=肠内管给药), Keyword(id=1329906156144800506, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=CN, orderNo=2, keyword=药品说明书信息缺失), Keyword(id=1329906156232880891, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=CN, orderNo=3, keyword=体外试验), Keyword(id=1329906156295795452, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=CN, orderNo=4, keyword=对比研究), Keyword(id=1329906156350321405, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=CN, orderNo=5, keyword=药物稳定性), Keyword(id=1329906156409041662, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, language=CN, orderNo=6, keyword=标准化流程)], refs=[Reference(id=1329906156589396736, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=郭雅乐, 李军文, 王红彦, 等.脑卒中后吞咽功能障碍患者早期肠内营养支持的研究进展[J].现代临床医学, 2024,50(1): 59-62., articleTitle=null, refAbstract=null), Reference(id=1329906156652311297, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=杨 光, 张 静.肠内营养[M].1版.北京: 人民卫生出版社, 2000, 3-4., articleTitle=null, refAbstract=null), Reference(id=1329906156748780290, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Oral drug products administered by enteral feeding tube: in vitro testing and labeling recommendations[EB/OL].(2022-12-01)[2025-01-01].https://www.fda.gov/media/149688/download., articleTitle=null, refAbstract=null), Reference(id=1329906156832666371, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=EMA.Clinical pharmacology and pharmacokinetics:questions and answers [EB/OL].(2025-02-22)[2025-02-27].https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/clinical-pharmacology-pharmacokinetics-questions-answers., articleTitle=null, refAbstract=null), Reference(id=1329906156895580932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心.国家药监局药审中心关于发布《化学仿制药口服制剂经肠内营养管给药体外对比研究技术指导原则》的通告(2025年第1号) [EB/OL].[2025-04-01].https://www.cde.org.cn/main/news/viewInfoCommon/b08545d339345358d423880f87a6c4b8., articleTitle=null, refAbstract=null), Reference(id=1329906156987855621, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on esomeprazole strontium[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole%20Strontium_draft_Oral%20cap%20DR_RLD%20202342_RC07-18.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157050770182, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on esomeprazole strontium[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole%20magnesium_oral%20DR%20suspension_NDA%20021957%20and%20022101_RV11-17.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157126267655, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on lansoprazole [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lansoprazole_draft_Oral%20cap%20DR_RLD%2020406_RC07-18.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157201765128, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on pantoprazole sodium [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Pantoprazole%20sodium_oral%20DR%20suspension_NDA%20022020_RV11-17.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157273068297, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on dexlansoprazole [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dexlansoprazole_oral%20DR%20capsule_NDA%20022287_RV11-17.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157356954378, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on dexlansoprazole [EB/OL].[2024-10-23]https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dexlansoprazole_orally%20disintegrating%20DR%20tablet_NDA%20208056_RV11-17.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157440840459, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on apixaban [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202155.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157528920844, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on rivaroxaban [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022406.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157617001229, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on edoxaban tosylate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206316.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157705081614, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on ticagrelor [EB/OL].[2024-12-28].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022433.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157797356303, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on morphine sulfate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/accessdata.fda.gov/drugsatfda_docs/psg/PSG_019516.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906157885436688, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on oxycodone hydrochloride[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208090.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158002877201, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on duloxetine hydrochloride[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212516.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158103540498, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on naloxegol oxalate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Naloxegol%20oxalate_oral%20tablet_NDA%20204760_RV11-17.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158216786707, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on cysteamine bitartrate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213491.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158304867092, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on cysteamine bitartrate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cysteamine%20bitartrate_oral%20DR%20capsule_NDA%20203389_RV11-17.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158388753173, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on carglumic acid [EB/OL].[2024-12-25].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022562.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158476833558, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on baclofen [EB/OL].(2024-02-15)[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215422.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158539748119, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on sodium phenylbutyrate; taurursodiol[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216660.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158648800024, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on uridine triacetate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208159.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158745269017, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on riluzole [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209080.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158837543706, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on baricitinib [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207924.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158904652571, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on vandetanib [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022405.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906158971761436, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on edaravone [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215446.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906159047258909, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on ruxolitinib phosphate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202192.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906159110173470, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on sodium polystyrene sulfonate[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_087859.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906159173088031, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on gefitinib [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206995.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906159236002592, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on osimertinib mesylate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208065.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906159290528545, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on ranolazine [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216018.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906159361831714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on maribavir [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215596.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906159416357667, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on brincidofovir [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214460.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906159475077924, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on baloxavir marboxil [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214410.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906159533798181, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Draft guidance on linaclotide [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202811.pdf., articleTitle=null, refAbstract=null), Reference(id=1329906159588324134, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=唐 谦, 郭艳超, 周 璐, 等.利伐沙班片经鼻胃管给药方式的体外试验研究[J].药学与临床研究, 2022, 30(1): 55-57., articleTitle=null, refAbstract=null), Reference(id=1329906159663821607, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=陈 思, 石 靖.口服固体仿制药经鼻胃管给药体外对比研究的思考[J].国际药学研究杂志, 2020, 47(7): 508-513., articleTitle=null, refAbstract=null), Reference(id=1329906159726736168, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=萧惠来.FDA“经肠内饲管给药的口服药品:体外试验和说明书建议”指导原则介绍[J].药物评价研究, 2021,44(9): 1843-1851., articleTitle=null, refAbstract=null), Reference(id=1329906159793845033, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=金佳敏, 俞 超, 崔冬冬, 等.鼻肠管失功的影响因素及干预策略的研究进展[J].现代临床护理, 2024, 23(9): 82-88., articleTitle=null, refAbstract=null), Reference(id=1329906159865148202, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=SWEDROWSKA M, INGHAM S, TOMLIN S, et al.Recommendations for crushing Circadin® (melatonin) tablets for safe and reliable delivery via pediatric nasogastric tubes[J].Int J Pharm, 2021, 594: 120151., articleTitle=null, refAbstract=null), Reference(id=1329906159932257067, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=SONG Y, WANG X L, PERLSTEIN I, et al.Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects [J].Clin Ther, 2015, 37(8): 1703-1712., articleTitle=null, refAbstract=null), Reference(id=1329906160020337452, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=BURY D, WOLFS T F W, TER HEINE R, et al.Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube [J].J Antimicrob Chemother, 2023, 78(12): 2886-2889., articleTitle=null, refAbstract=null), Reference(id=1329906160121000749, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=李瑶瑶, 范 苗, 朱素燕, 等.包衣药物经鼻饲给药的风险控制及合理使用[J].中国临床药学杂志, 2022, 31(3):235-240., articleTitle=null, refAbstract=null), Reference(id=1329906160179721006, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=SHAH S A, SANDER S, COLEMAN C I, et al.Delivery of esomeprazole magnesium through nasogastric and gastrostomy tubes using an oral liquid vehicle as a suspending agent in vitro[J].Am J Health Syst Pharm, 2006, 63(19): 1882-1887., articleTitle=null, refAbstract=null), Reference(id=1329906160246829871, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=SPILIOS M, ALTSHULER J, RADPARVAR S.Safety and feasibility of crushing sevelamer tablets for enteral feeding tube administration [J].J Clin Pharm Ther, 2021, 46(2):369-372., articleTitle=null, refAbstract=null), Reference(id=1329906160309744432, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=CARABALLO M L, DONMEZ S, NATHAN K, et al.Compounded apixaban suspensions for enteral feeding tubes[J].Hosp Pharm, 2017, 52(7): 478-482., articleTitle=null, refAbstract=null), Reference(id=1329906160393630513, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=李瑶瑶, 范 苗, 朱素燕, 等.包衣药物经鼻饲给药的风险控制及合理使用[J].中国临床药学杂志, 2022, 31(3):235-240., articleTitle=null, refAbstract=null), Reference(id=1329906160456545074, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=杜玫洁, 王 颖, 何 梅, 等.经饲管给药规范性实践障碍因素及干预策略的研究进展[J].中华急危重症护理杂志, 2023, 4(1): 92-96., articleTitle=null, refAbstract=null), Reference(id=1329906160523653939, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=CHIU J W, CHAN K, CHEN E X, et al.Pharmacokinetic assessment of dacomitinib(pan-HER tyrosine kinase inhibitor)in patients with locally advanced head and neck squamous cell carcinoma(LA SCCHN) following administration through a gastrostomy feeding tube(GT)[J].Invest New Drugs, 2015,33(4): 895-900., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329906156492927743, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, awardId=2024H028, language=CN, fundingSource=国家药典委员会国家药品标准制修订研究课题(2024H028), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)]), AuthorCompany(id=1329906154282529493, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=2., ext=[AuthorCompanyExt(id=1329906154290918102, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154282529493, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China Pharmaceutical University, Nanjing 210009), AuthorCompanyExt(id=1329906154299306711, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154282529493, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国药科大学,江苏 南京 210009)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2025.12.003, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2025.12.003, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2025.12.003, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2025.12.003, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1765296000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
肠内管给药指导原则现状及体外对比试验评价概述
庄杰 1, 2 , 綦梦洁 1 , 张文婧 1 , 牛剑钊 1 , 刘倩 1, *
中国医药工业杂志 | 专论与综述 2025,56(12): 1514-1523
收起
收藏切换
中国医药工业杂志 |专论与综述 2025 , 56 (12) : 1514 -1523
肠内管给药指导原则现状及体外对比试验评价概述
全屏
[Author(id=1329906154362221274, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329906154441913053, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154362221274, language=EN, stringName=Jie ZHUANG, firstName=Jie, middleName=null, lastName=ZHUANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.China National Institutes for Food and Drug Control, Beijing 100050
2.China Pharmaceutical University, Nanjing 210009, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329906154538382046, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154362221274, language=CN, stringName=庄杰, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.中国食品药品检定研究院,北京 100050
2.中国药科大学,江苏 南京 210009, bio={"content":"

庄杰,硕士研究生,专业方向:药物质量控制。

"}, bioImg=null, bioContent=

庄杰,硕士研究生,专业方向:药物质量控制。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)]), AuthorCompany(id=1329906154282529493, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=2., ext=[AuthorCompanyExt(id=1329906154290918102, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154282529493, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.China Pharmaceutical University, Nanjing 210009), AuthorCompanyExt(id=1329906154299306711, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154282529493, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.中国药科大学,江苏 南京 210009)])]), Author(id=1329906154626462432, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329906154689376994, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154626462432, language=EN, stringName=Mengjie QI, firstName=Mengjie, middleName=null, lastName=QI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.China National Institutes for Food and Drug Control, Beijing 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329906154756485859, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154626462432, language=CN, stringName=綦梦洁, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国食品药品检定研究院,北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)])]), Author(id=1329906154819400421, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329906154903286503, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154819400421, language=EN, stringName=Wenjing ZHANG, firstName=Wenjing, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.China National Institutes for Food and Drug Control, Beijing 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329906154962006760, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906154819400421, language=CN, stringName=张文婧, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国食品药品检定研究院,北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)])]), Author(id=1329906155037504234, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329906155146556140, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906155037504234, language=EN, stringName=Jianzhao NIU, firstName=Jianzhao, middleName=null, lastName=NIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.China National Institutes for Food and Drug Control, Beijing 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329906155238830829, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906155037504234, language=CN, stringName=牛剑钊, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.中国食品药品检定研究院,北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)])]), Author(id=1329906155360465647, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329906155498877681, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906155360465647, language=EN, stringName=Qian LIU, firstName=Qian, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.China National Institutes for Food and Drug Control, Beijing 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329906155570180850, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, authorId=1329906155360465647, language=CN, stringName=刘倩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.中国食品药品检定研究院,北京 100050, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329906154202837714, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, xref=1., ext=[AuthorCompanyExt(id=1329906154211226323, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.China National Institutes for Food and Drug Control, Beijing 100050), AuthorCompanyExt(id=1329906154219614932, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1329906153464640206, companyId=1329906154202837714, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.中国食品药品检定研究院,北京 100050)])])]
庄杰1, 2, 綦梦洁1, 张文婧1, 牛剑钊1, 刘倩1, *
作者信息
  • 1.中国食品药品检定研究院,北京 100050
  • 2.中国药科大学,江苏 南京 210009
通讯作者:
刘倩,博士,研究员,从事药物质量控制的研究。
作者简介:

庄杰,硕士研究生,专业方向:药物质量控制。

Current Status of Enteral Tube Administration Guidelines and Overview of in vitro Comparative Testing Evaluation
Jie ZHUANG1, 2, Mengjie QI1, Wenjing ZHANG1, Jianzhao NIU1, Qian LIU1, *
Affiliations
  • 1.China National Institutes for Food and Drug Control, Beijing 100050
  • 2.China Pharmaceutical University, Nanjing 210009
出版时间: 2025-12-10 doi: 10.16522/j.cnki.cjph.2025.12.003
文章导航
收藏切换

肠内管给药是吞咽障碍患者重要的口服替代治疗途径,但其临床应用面临标准化不足、药物说明书指导缺失及体外评价体系待完善等多重挑战。美国FDA已发布了30余种药品(如艾司奥美拉唑胶囊、利伐沙班片等)肠内管给药技术指南,明确了试验参数(肠内管管径、分散介质种类与体积、孵育时间等)。目前,我国仿制药说明书中的肠内管给药信息缺失或不完整问题突出,可能导致临床操作误差及药物稳定性风险。该文围绕经肠内管给药的相关技术指南、国内外临床应用现状和研究进展,以及目前存在的问题进行综述,重点总结开展体外对比研究时需要注意的关键点,以期为经肠内管给药的口服药物体外试验的设计、实施以及结果评价提供技术建议。

肠内管给药  /  药品说明书信息缺失  /  体外试验  /  对比研究  /  药物稳定性  /  标准化流程

Enteral tube administration is an important oral alternative treatment route for patients with dysphagia.However, its clinical application faces multiple challenges, such as insufficient standardization, lack of guidance in drug package inserts, and an immature in vitro evaluation system. The U.S. FDA has issued enteral tube administration technical guidelines for more than 30 types of drugs(e.g., esomeprazole capsules, rivaroxaban tablets), clearly specifying test parameters(including enteral tube diameter, types and volumes of dispersion medium, incubation time). Currently, the problem of missing or incomplete information related to enteral tube administration in the package inserts of generic drugs in China is prominent, which may lead to clinical operation errors and risks to drug stability. This article reviews the relevant technical guidelines for enteral tube administration, the current status and research progress of clinical applications at home and abroad, as well as the existing problems. It focuses on summarizing the key points to be noted when conducting in vitro comparative studies, aiming to provide technical suggestions for the design, implementation, and result evaluation of in vitro tests for oral drugs administered via enteral tubes.

enteral tube administration  /  lack of information in the drug package insert  /  in vitro test  /  comparative study  /  drug stability  /  standardized procedure
庄杰, 綦梦洁, 张文婧, 牛剑钊, 刘倩. 肠内管给药指导原则现状及体外对比试验评价概述. 中国医药工业杂志, 2025 , 56 (12) : 1514 -1523 . DOI: 10.16522/j.cnki.cjph.2025.12.003
Jie ZHUANG, Mengjie QI, Wenjing ZHANG, Jianzhao NIU, Qian LIU. Current Status of Enteral Tube Administration Guidelines and Overview of in vitro Comparative Testing Evaluation[J]. Chinese Journal of Pharmaceuticals, 2025 , 56 (12) : 1514 -1523 . DOI: 10.16522/j.cnki.cjph.2025.12.003
  • 国家药典委员会国家药品标准制修订研究课题(2024H028)
参考文献 引证文献
排序方式:
[1]
郭雅乐, 李军文, 王红彦, 等.脑卒中后吞咽功能障碍患者早期肠内营养支持的研究进展[J].现代临床医学, 2024,50(1): 59-62.
[2]
杨 光, 张 静.肠内营养[M].1版.北京: 人民卫生出版社, 2000, 3-4.
[3]
FDA.Oral drug products administered by enteral feeding tube: in vitro testing and labeling recommendations[EB/OL].(2022-12-01)[2025-01-01].https://www.fda.gov/media/149688/download.
[4]
EMA.Clinical pharmacology and pharmacokinetics:questions and answers [EB/OL].(2025-02-22)[2025-02-27].https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/clinical-pharmacology-pharmacokinetics-questions-answers.
[5]
国家药品监督管理局药品审评中心.国家药监局药审中心关于发布《化学仿制药口服制剂经肠内营养管给药体外对比研究技术指导原则》的通告(2025年第1号) [EB/OL].[2025-04-01].https://www.cde.org.cn/main/news/viewInfoCommon/b08545d339345358d423880f87a6c4b8.
[6]
FDA.Draft guidance on esomeprazole strontium[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole%20Strontium_draft_Oral%20cap%20DR_RLD%20202342_RC07-18.pdf.
[7]
FDA.Draft guidance on esomeprazole strontium[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole%20magnesium_oral%20DR%20suspension_NDA%20021957%20and%20022101_RV11-17.pdf.
[8]
FDA.Draft guidance on lansoprazole [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Lansoprazole_draft_Oral%20cap%20DR_RLD%2020406_RC07-18.pdf.
[9]
FDA.Draft guidance on pantoprazole sodium [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Pantoprazole%20sodium_oral%20DR%20suspension_NDA%20022020_RV11-17.pdf.
[10]
FDA.Draft guidance on dexlansoprazole [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dexlansoprazole_oral%20DR%20capsule_NDA%20022287_RV11-17.pdf.
[11]
FDA.Draft guidance on dexlansoprazole [EB/OL].[2024-10-23]https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dexlansoprazole_orally%20disintegrating%20DR%20tablet_NDA%20208056_RV11-17.pdf.
[12]
FDA.Draft guidance on apixaban [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202155.pdf.
[13]
FDA.Draft guidance on rivaroxaban [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022406.pdf.
[14]
FDA.Draft guidance on edoxaban tosylate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206316.pdf.
[15]
FDA.Draft guidance on ticagrelor [EB/OL].[2024-12-28].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022433.pdf.
[16]
FDA.Draft guidance on morphine sulfate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/accessdata.fda.gov/drugsatfda_docs/psg/PSG_019516.pdf.
[17]
FDA.Draft guidance on oxycodone hydrochloride[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208090.pdf.
[18]
FDA.Draft guidance on duloxetine hydrochloride[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_212516.pdf.
[19]
FDA.Draft guidance on naloxegol oxalate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Naloxegol%20oxalate_oral%20tablet_NDA%20204760_RV11-17.pdf.
[20]
FDA.Draft guidance on cysteamine bitartrate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_213491.pdf.
[21]
FDA.Draft guidance on cysteamine bitartrate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/Cysteamine%20bitartrate_oral%20DR%20capsule_NDA%20203389_RV11-17.pdf.
[22]
FDA.Draft guidance on carglumic acid [EB/OL].[2024-12-25].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022562.pdf.
[23]
FDA.Draft guidance on baclofen [EB/OL].(2024-02-15)[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215422.pdf.
[24]
FDA.Draft guidance on sodium phenylbutyrate; taurursodiol[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216660.pdf.
[25]
FDA.Draft guidance on uridine triacetate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208159.pdf.
[26]
FDA.Draft guidance on riluzole [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209080.pdf.
[27]
FDA.Draft guidance on baricitinib [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_207924.pdf.
[28]
FDA.Draft guidance on vandetanib [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022405.pdf.
[29]
FDA.Draft guidance on edaravone [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215446.pdf.
[30]
FDA.Draft guidance on ruxolitinib phosphate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202192.pdf.
[31]
FDA.Draft guidance on sodium polystyrene sulfonate[EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_087859.pdf.
[32]
FDA.Draft guidance on gefitinib [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_206995.pdf.
[33]
FDA.Draft guidance on osimertinib mesylate [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_208065.pdf.
[34]
FDA.Draft guidance on ranolazine [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_216018.pdf.
[35]
FDA.Draft guidance on maribavir [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_215596.pdf.
[36]
FDA.Draft guidance on brincidofovir [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214460.pdf.
[37]
FDA.Draft guidance on baloxavir marboxil [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_214410.pdf.
[38]
FDA.Draft guidance on linaclotide [EB/OL].[2024-10-23].https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_202811.pdf.
[39]
唐 谦, 郭艳超, 周 璐, 等.利伐沙班片经鼻胃管给药方式的体外试验研究[J].药学与临床研究, 2022, 30(1): 55-57.
[40]
陈 思, 石 靖.口服固体仿制药经鼻胃管给药体外对比研究的思考[J].国际药学研究杂志, 2020, 47(7): 508-513.
[41]
萧惠来.FDA“经肠内饲管给药的口服药品:体外试验和说明书建议”指导原则介绍[J].药物评价研究, 2021,44(9): 1843-1851.
[42]
金佳敏, 俞 超, 崔冬冬, 等.鼻肠管失功的影响因素及干预策略的研究进展[J].现代临床护理, 2024, 23(9): 82-88.
[43]
SWEDROWSKA M, INGHAM S, TOMLIN S, et al.Recommendations for crushing Circadin® (melatonin) tablets for safe and reliable delivery via pediatric nasogastric tubes[J].Int J Pharm, 2021, 594: 120151.
[44]
SONG Y, WANG X L, PERLSTEIN I, et al.Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects [J].Clin Ther, 2015, 37(8): 1703-1712.
[45]
BURY D, WOLFS T F W, TER HEINE R, et al.Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube [J].J Antimicrob Chemother, 2023, 78(12): 2886-2889.
[46]
李瑶瑶, 范 苗, 朱素燕, 等.包衣药物经鼻饲给药的风险控制及合理使用[J].中国临床药学杂志, 2022, 31(3):235-240.
[47]
SHAH S A, SANDER S, COLEMAN C I, et al.Delivery of esomeprazole magnesium through nasogastric and gastrostomy tubes using an oral liquid vehicle as a suspending agent in vitro[J].Am J Health Syst Pharm, 2006, 63(19): 1882-1887.
[48]
SPILIOS M, ALTSHULER J, RADPARVAR S.Safety and feasibility of crushing sevelamer tablets for enteral feeding tube administration [J].J Clin Pharm Ther, 2021, 46(2):369-372.
[49]
CARABALLO M L, DONMEZ S, NATHAN K, et al.Compounded apixaban suspensions for enteral feeding tubes[J].Hosp Pharm, 2017, 52(7): 478-482.
[50]
李瑶瑶, 范 苗, 朱素燕, 等.包衣药物经鼻饲给药的风险控制及合理使用[J].中国临床药学杂志, 2022, 31(3):235-240.
[51]
杜玫洁, 王 颖, 何 梅, 等.经饲管给药规范性实践障碍因素及干预策略的研究进展[J].中华急危重症护理杂志, 2023, 4(1): 92-96.
[52]
CHIU J W, CHAN K, CHEN E X, et al.Pharmacokinetic assessment of dacomitinib(pan-HER tyrosine kinase inhibitor)in patients with locally advanced head and neck squamous cell carcinoma(LA SCCHN) following administration through a gastrostomy feeding tube(GT)[J].Invest New Drugs, 2015,33(4): 895-900.
2025年第56卷第12期
26
8
0
引用本文
BibTeX
文章信息
doi: 10.16522/j.cnki.cjph.2025.12.003
  • 接收时间:2025-05-02
  • 首发时间:2026-11-18
  • 出版时间:2025-12-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-05-02
基金
国家药典委员会国家药品标准制修订研究课题(2024H028)
作者信息
    1.中国食品药品检定研究院,北京 100050
    2.中国药科大学,江苏 南京 210009

通讯作者:

刘倩,博士,研究员,从事药物质量控制的研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2025.12.003
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏